-+ 0.00%
-+ 0.00%
-+ 0.00%

Corning (GLW) Stock Shrugs Off Strong Q3 Earnings Momentum

Simply Wall St·10/28/2026 00:32:12
Listen to the news

Corning stock barely flinched after its Q3 2026 report, slipping about 1% to US$126.30, even as the quarter landed with real weight. The company just printed Basic EPS of US$0.79 on US$4.86b in sales, backed by a trailing net profit margin of 12.1% that sits above last year’s 9.2%. The near term reaction looks muted. The longer lens, shaped by forecasts for double digit revenue growth and expectations that earnings will compound faster than the wider US market, is where this earnings story starts to matter for multi year holders.

Love Corning’s higher net margin but want more ideas where profits and balance sheets work together in the same way? Scan through the list of solid balance sheet and fundamentals stocks (24 results).

Q3 2026 Earnings Summary

  • Revenue, Q3 2026 vs. Q3 2025: US$4,855m vs. US$4,100m (up about 18%)
  • Net Income (Excl. Extra Items), Q3 2026 vs. Q3 2025: US$680m vs. US$430m (up about 58%)
  • Basic EPS, Q3 2026 vs. Q3 2025: US$0.79 vs. US$0.50 (up about 57%)
  • Trailing Net Profit Margin, last 12 months vs. prior year: 12.1% vs. 9.2% (margin higher year over year)

Earnings show how Q3 landed, but the cash flowing through Corning’s business is what many valuation focused investors focus on when they think in multi year terms. Based on cash flows alone, Corning’s profile suggests the stock could be a hefty 36% undervalued.

NYSE:GLW Trailing 12-Month Earnings & Revenue History as at Oct 2026
NYSE:GLW Trailing 12-Month Earnings & Revenue History as at Oct 2026

Evaluating Corning’s Springboard Milestones So Far

The bullish script says Corning’s Springboard plan turns high growth in optical, automotive and solar into faster compounding profits. That ambition is explicit.

"Bullish analysts expect Corning to convert high-teens company-wide growth targets in optical, automotive and solar into sustained margin expansion and earnings growing faster than sales over the Springboard 20-30-40 plan."

Q3 results show pieces of that playing out. Optical Communications logged 44% sales growth with segment net income up 80%, which points to profits outpacing revenue where AI demand is strongest. Group operating margin reached 22.7% and ROIC 16.7%, both aligned with the higher return profile targeted by Springboard. Solar is not there yet, with a small loss on US$436m of sales, so the margin story is still uneven across the portfolio.

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.

Corning Bear Case: Equity Overhang vs Execution Gains

The cautious view hinges on capital allocation and execution risk rather than demand. One recurring concern is clear.

"Although Corning points to strong recent optical demand tied to Gen AI data centers, the new at the market equity program of up to US$2b suggests that higher share count could absorb a meaningful portion of any future earnings uplift."

Q3 results cut against that fear on operations. Optical Communications net income increased faster than sales, group operating margin reached 22.7%, ROIC was 16.7% and free cash flow was US$661m. Yet the stock slipped about 1% and is down about 19% over 30 days, which suggests the equity overhang is not resolved by one strong quarter.

Hunt For Mispriced Earnings Power

Corning recently highlighted how execution strength and share price can diverge. The real opportunity is in stocks that could be undervalued before that gap narrows.

  • Company 1 - 38% below our estimate - uses government-backed trade-in programs and recommerce technology to convert discarded devices into recurring, higher quality transaction volume.
  • Company 2 - 23% below our estimate - expands robotic surgery platforms into new joint procedures while reworking manufacturing and supply chains for higher margin medical hardware.
  • Company 3 - 26% below our estimate - sells weight loss and diabetes therapies as patients and doctors shift toward injectable treatments amid constrained supply.

That is three of the list. See the full list of 29 companies trading below our fair value estimates →